SCHEMBL2968436

SCHEMBL2968436

Cc1ccc(C(=O)Nc2cccc(N3CCOCC3)c2)cc1NC(=O)c1cccc(OCc2ccccc2)c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 9/20 0.82
SMO Q99835 1/20 0.65
KMT2A Q03164 3/20 0.60
MAPT P10636 2/20 0.60
USP2 O75604 1/20 0.60
MAPK1 P28482 1/20 0.60
ESR2 Q92731 1/20 0.60
TAAR1 Q96RJ0 1/20 0.60
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.59
HPGD P15428 1/20 0.59
HTT P42858 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
KDM4E B2RXH2 1/20 0.59
LMNA P02545 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
RAF1 P04049 2/20 0.55
BRAF P15056 2/20 0.55
NR1H4 Q96RI1 1/20 0.55
SIRT2 Q8IXJ6 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485519 0.94 MAPK14 (0.89) MAPK14SMOKMT2AMAPTUSP2
SCHEMBL7846077 0.93 MAPK14 (0.73) MAPK14SMOKMT2AMAPTUSP2
SCHEMBL7807977 0.93 MAPK14 (0.78) MAPK14SMOKMT2AMAPTUSP2
SCHEMBL6477445 0.90 MAPK14 (1.00) MAPK14SMOKMT2AMAPTUSP2
SCHEMBL7807923 0.87 MAPK14 (0.85) MAPK14SMOKMT2AMAPTMEN1
SCHEMBL7679107 0.85 MAPK14 (0.72) MAPK14SMOKMT2AMAPTUSP2
SCHEMBL2979099 0.84 MAPK14 (0.65) MAPK14SMORAF1BRAF
SCHEMBL2970434 0.84 MAPK14 (0.64) MAPK14SMORAF1BRAF
SCHEMBL340905 0.84 ALDH1A1 (0.66) MAPK14KMT2AMAPTUSP2MAPK1
SCHEMBL2345986 0.82 KMT2A (0.67) MAPK14SMOKMT2AMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7772432-B2 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA AB (SE) 2010-08-10 US disclosed
CN-1243724-C Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2006-03-01 CN disclosed
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors ASTRAZENECA 2005-02-17 US disclosed
US-6821965-B1 IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION ASTERZENECA AB (SE) 2004-11-23 US disclosed
CN-1330631-A Amide derivatives which are useful as cell factor inhibitors ASTRA ZENECA LTD (SE) 2002-01-09 CN disclosed
EP-1102743-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS AstraZeneca AB (SE) 2001-05-30 EP disclosed
WO-2000007980-A1 AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS ASTRAZENECA AB (SE) 2000-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038081-A1 Amidobenzamide derivatives which are useful as cytokine inhibitors IL6, IL6ST, IL2 MAPK14 1775/4885SMO 4706/4885KMT2A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.